The College of American Pathologists has awarded accreditation to the Theralink Technologies', a precision oncology company with a novel phosphoprotein-based assay for breast cancer. Accreditation was awarded to its Reverse Phase Protein Array laboratory in Golden, Colorado.
For the full article click here: Theralink® Technologies Achieves the First College of American Pathologists Accreditation for a Commercial Reverse Phase Protein Array Laboratory in U.S. - Theralink Technologies (OTC:THER)